Insider · CIK 0001245624
James Healy
director
Files at NTRA (Natera, Inc.), BIOA (BioAge Labs, Inc.), YMAB (Y-mAbs Therapeutics, Inc.), RAPP (Rapport Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stock | -31,603 | $8.60 | $272k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | UTender of shares Common Stockindirect: See footnote | -2,194,278 | $8.60 | $19M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,222 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -8,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -13,950 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,545 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -33,450 | - | - | 0 | Sep 18, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Common Stock | +25,080 | $0.00 | $0 | 56,683 | Jul 2, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +33,450 | $0.00 | $0 | 33,450 | Jul 2, 2025 |
| Jun 17, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,850 | $0.00 | $0 | 21,850 | Jun 18, 2025 |
| Jun 5, 2025 | BIOA BioAge Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Apr 25, 2025 | NTRA Natera, Inc. | AGrant or award Common Stock | +142 | - | - | 46,260 | Apr 29, 2025 |
| Jan 31, 2025 | NTRA Natera, Inc. | AGrant or award Common Stock | +114 | - | - | 46,118 | Feb 4, 2025 |
| Oct 25, 2024 | NTRA Natera, Inc. | AGrant or award Common Stock | +153 | - | - | 46,004 | Oct 29, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.